AbCellera Biologics Inc. (ABCL) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2022
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, AbCellera Biologics Inc. (ABCL) trades at a price-to-earnings ratio of -7.4x, with a stock price of $3.61 and trailing twelve-month earnings per share of $-0.49.
The current P/E is 122% below its 5-year average of 34.2x. Over the past five years, ABCL's P/E has ranged from a low of 12.5x to a high of 106.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, ABCL trades at a 131% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, ABCL trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABCL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Drug Discovery and Antibody Platforms peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
REGNRegeneron Pharmaceuticals, Inc. | $108B | 18.8 | 2.98Best | +8% |
CTMXCytomX Therapeutics, Inc. | $430M | 14.1 | - | - |
PRTCPureTech Health plc | $405M | 8.4Lowest | - | +183%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $10.13 | $0.50 | 20.2x | -41% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $9.89 | $0.79 | 12.5x | -63% |
| FY2022 Q2 | $10.65 | $0.63 | 16.9x | -51% | |
| FY2022 Q1 | $9.75 | $0.64 | 15.2x | -55% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $14.30 | $0.47 | 30.4x | -11% |
| FY2021 Q3 | $20.04 | $0.65 | 30.8x | -10% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $22.00 | $0.72 | 30.6x | -11% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $33.96 | $0.76 | 44.8x | +31% |
| FY2020 Q4 | $40.24 | $0.38 | 106.3x | +211% |
Average P/E for displayed period: 34.2x
See ABCL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABCL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ABCL vs AGIO
See how ABCL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ABCL stock overvalued or undervalued?
ABCL trades at -7.4x P/E, below its 5-year average of 34.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ABCL's valuation compare to peers?
AbCellera Biologics Inc. P/E of -7.4x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is ABCL's PEG ratio?
ABCL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2022.